Bill Ackman Adds Two Positions to Portfolio in 1QFY15

Author's Avatar
May 19, 2015
Article's Main Image

Bill Ackman (Trades, Portfolio) added two new positions to his portfolio, according to GrurFocus Real Time Picks. The new additions bring his number of stocks to a total of eight and valued around $14.97 billion. His portfolio's quarter-over-quarter turnover is 29%.

Ackman purchased 19,473,933 shares of Valeant Pharmaceuticals International Inc (VRX, Financial) at an average price of $177.40 a share.

Valeant is a multinational, specialty pharmaceutical and medical device company that develops, markets and manufactures numerous branded or generic pharmaceuticals, over-the-counter products and media devices.

03May20171113141493827994.png

The Peter Lynch earnings line is currently at $42.10 and the stock is trading at $225.86, which indicates that it may be currently overvalued.

03May20171113151493827995.png

EBITDA per share for the trailing twelve months as of March 2015 was $11.73 and its growth rate was 144.70% for the past year.

1,348,358 shares of Actavis PLC (ACT, Financial) were purchased at an average price of $285.10 a share.

Actavis is an integrated pharmaceutical company that develops, manufactures, markets, sales and distributes generic and branded over-the-counter pharmaceutical products. The company was incorporated in 2013. The stock is currently trading at $295.76 a share.

The company's current ratio is at a comfortable 1.44, which indicates that it has good short-term financial strength.

For a complete list of positions in Ackman's portfolio, click here.